A new study published by the Oxford journal Carcinogenesis, and published online by the U.S. National Institute of Health, has found that the cannabis compound cannabigerol can prevent the progression of cancer cells formed in the colon.
“Cannabigerol (CBG) is a safe non-psychotropic Cannabis-derived cannabinoid which interacts with specific targets involved in carcinogenesis [the creation of cancer cells]”, begins the study’s abstract. “Here, we investigated whether CBG protects against colon tumorigenesis.”
After studying the effect of CBG on colon cancer cells, researchers found that; “In vivo, CBG inhibited the growth of xenograft tumors as well as chemically-induced colon carcinogenesis. CBG hampers colon cancer progression in vivo and selectively inhibits the growth of colorectal cancer cells.”
They study concludes; “CBG should be considered translationally in colorectal cancer prevention and cure.”
These results are similar to a study published earlier this year in the journal Phytomedicine, which found that the cannabis compound cannabidiol “attenuates colon carcinogenesis and inhibits colorectal cancer cell proliferation via CB1 and CB2 receptor activation.”